Javier Zarzoso-Foj

Mr. Javier Zarzoso-Foj

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KFKarine Elena Rodriguez Fernandez
Karine Elena Rodriguez Fernandez
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
MBMarina Sáez Belló
Marina Sáez Belló
AMAlmudena Mateu-Puchades
Almudena Mateu-Puchades
AMAntonio Martorell
Antonio Martorell
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
Background/Objectives: Implementing model-informed precision dosing (MIPD) strategies guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance the management of inflammatory diseases such as psoriasis. However, the extent of individual experimental data gathered during MIPD significantly influences the uncertainty in estimating individual PK/PD parameters, affecting clinical dose selection decisions. Methods: This study proposes a methodology to individualize ustekinumab (UTK) dosing strategies for 23 Spanish patients with moderate to severe chronic plaque psoriasis., considering the uncertainty of individual parameters within a population PK/PD model. Results: An indirect response model from previous research was used to describe the PK/PD relationship between UTK serum concentrations and the Psoriasis Area and Severity Index (PASI) score. A maximum inhibition drug effect (Imax) model was selected, and a first-order remission constant rate of psoriatic skin lesion (kout = 0.016 d−1) was estimated. Conclusions: The MIPD approach predicted that 35% and 26% of the patients would need an optimized and intensified dosage regimen, respectively, compared to the regimen typically used in clinical practice. This analysis demonstrated its utility as a tool for selecting personalized UTK dosing regimens in clinical practice in order to optimize the probability of achieving targeted clinical outcomes in patients with psoriasis.

21 August 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GAGloria M. Alfosea-Cuadrado
Gloria M. Alfosea-Cuadrado
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
AAAlbert Adell
Albert Adell
AVALFONSO AMADOR VALVERDE-NAVARRO
ALFONSO AMADOR VALVERDE-NAVARRO
Eva María González-SolerEva María González-Soler
Eva María González-Soler
ASArantxa Blasco Serra
Arantxa Blasco Serra
(1) Background: Fibromyalgia syndrome (FMS) is a chronic pain condition with widespread pain and multiple comorbidities, for which conventional therapies offer limited benefits. The reserpine-induced myalgia (RIM) model is an efficient animal model of FMS in rodents. This study aimed to develop a pharmacokinetic–pharmacodynamic (PK–PD) model of reserpine in rats, linking to its impact on monoamines (MAs). (2) Methods: Reserpine was administered daily for three consecutive days at dose levels of 0.1, 0.5, and 1 mg/kg. A total of 120 rats were included, and 120 PK and 828 PD observations were collected from 48 to 96 h after the first dose of reserpine. Non-linear mixed-effect data analysis was applied for structural PK–PD model definition, variability characterization, and covariate analysis. (3) Results: A one-compartment model best described reserpine in rats (V = 1.3 mL/kg and CL = 4.5 × 10−1 mL/h/kg). A precursor-pool PK–PD model (kin = 6.1 × 10−3 mg/h, kp = 8.6 × 10−4 h−1 and kout = 2.7 × 10−2 h−1) with a parallel transit chain (k0 = 1.9 × 10−1 h−1) characterized the longitudinal levels of MA in the prefrontal cortex, spinal cord, and amygdala in rats. Reserpine stimulates the degradation of MA from the pool compartment (Slope1 = 1.1 × 10−1 h) and the elimination of MA (Slope2 = 1.25 h) through the transit chain. Regarding the reference dose (1 mg/kg) of the RIM model, the administration of 4 mg/kg would lead to a mean reduction of 65% (Cmax), 80% (Cmin), and 70% (AUC) of MA across the brain regions tested. (4) Conclusions: Regional brain variations in neurotransmitter depletion were identified, particularly in the amygdala, offering insights for therapeutic strategies and biomarker identification in FMS research.

10 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KFKarine Elena Rodriguez Fernandez
Karine Elena Rodriguez Fernandez
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
MBMarina Sáez Belló
Marina Sáez Belló
AMAlmudena Mateu-Puchades
Almudena Mateu-Puchades
AMAntonio Martorell
Antonio Martorell
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
Background/Objectives: Patient care and control of inflammatory disorders, such as psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based on population pharmacokinetic/pharmacodynamic (PK/PD) models. Clinical dose selection decisions based on MIPD strategies need to take account of the uncertainty associated with the individual PK/PD model parameters, which is determined by the quantity of individual observational data collected in clinical practice. Methods: The aim of this study was to propose an approach for personalized dosage regimens of secukinumab (SCK) in 22 Spanish patients with plaque psoriasis, whose severity level was considered moderate to severe, taking into account the uncertainty associated with individual parameters in a population-based PK/PD model. Results: The link between SCK serum concentrations and Psoriasis Area and Severity Index (PASI) scores was explained using an indirect response model. A maximum inhibition (Imax) drug effect model was applied to limit the progression of psoriatic skin lesions within the turnover PD mechanism, which explains the changes in PASI scores during treatment. A first-order remission rate constant for psoriatic lesions (kout = 0.11 day−1) was estimated. Conclusions: According to the MIPD strategy, 50% of patients would require an optimized regimen and 14% would require an intensified dosage regimen in comparison to current clinical treatment. This research has shown its usefulness as a tool for choosing individualized SCK dosage regimens in patients with long-lasting plaque psoriasis to improve the probability of achieving satisfactory response levels.

24 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
MCMarina Cuquerella-Gilabert
Marina Cuquerella-Gilabert
MMMatilde Merino-Sanjuán
Matilde Merino-Sanjuán
JLJavier Reig López
Javier Reig López
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
AGAlfredo García-Arieta
Alfredo García-Arieta
Background: Physiologically based pharmacokinetic (PBPK) modeling for biopharmaceutics applications (i.e., physiologically based biopharmaceutics modeling (PBBM)) enables mechanistic modeling from dissolution to absorption and disposition, facilitating the prediction of bioequivalence (BE) outcomes and the delimitation of the safe space. This study aims to identify the product-related parameter driving ibuprofen dissolution to upgrade an existing PBPK model, so that an in vitro safe space and virtual BE (VBE) predictions of IR ibuprofen tablets can be performed. Methods: Cmax within- and between-subject variabilities of a previous PBPK model were optimized after identifying crucial physiological parameters for ibuprofen absorption and disposition. In vitro data modeling was performed to estimate the value of the parameter driving ibuprofen dissolution. A safe space was defined for this parameter and the sample size to declare BE was calculated. Finally, VBE simulations were performed to explore the effect of sample size as well as number of trial replicates and runs. Results: Cmax variability was adequately predicted after changing Vss and MRT in stomach and small intestine CV (%) to 10 and 150%, respectively. Particle surface pH was identified as the dissolution key parameter for ibuprofen. A safe space for test product surface pH values of 5.64–6.40 was defined in order to achieve a 90%CI for the Cmax ratio within the 80–125% range when the reference product surface pH is 6.02. R-ibuprofen was identified as the most discriminative enantiomer. VBE studies with 24 individuals showed BE outcomes that are sensitive to the number of trial replicates and runs. Conclusions: Ibuprofen particle surface pH has been identified as the in vitro parameter governing dissolution in maleate buffer 7 mM with HCl pH 2.0 pretreatment, allowing to establish an in vitro safe space useful for calculating sample sizes and to evaluate the BE success rate through PBBM/PBPK model-informed VBE simulations.

2 September 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
MCMarina Cuquerella-Gilabert
Marina Cuquerella-Gilabert
JRJavier Reig-López
Javier Reig-López
VMVíctor Mangas-Sanjuán
Víctor Mangas-Sanjuán
AGAlfredo García-Arieta
Alfredo García-Arieta

4 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJavier Reig López
Javier Reig López
MCMarina Cuquerella-Gilabert
Marina Cuquerella-Gilabert
JZJavier Zarzoso-Foj
Javier Zarzoso-Foj
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
VMVirginia Merino
Virginia Merino
MMMatilde Merino-Sanjuán
Matilde Merino-Sanjuán
Background/Objectives: While intravitreal administration allows for increased ocular exposure to anti-TNF-α monoclonal antibodies, there is still a need for developing delivery systems able to prolong ocular drug exposure and alleviate patient compliance and safety concerns because of repeated injections. Therefore, the objective of this work was to guide the design of sustained-release formulations of anti-TNF-α monoclonal antibodies for intravitreal administration through a model-based strategy in non-infectious uveitis in the preclinical setting. Methods: Using an in-house-developed anterior uveitis disease model in rats, an intravenous reference dose reducing free TNF-α by 90% at the biophase was established. Intravitreal administrations of sustained-release formulations every 24 weeks were then simulated for adalimumab, golimumab and infliximab to evaluate TNF-α kinetics in the anterior chamber of the eye at different release rates. The selected sustained-release formulation was further evaluated for possible formulation issues causing device emptying before the next administration. Results: Intravitreal administration of sustained-release formulations releasing adalimumab, golimumab or infliximab at 1.802, 0.979 and 1.442 μg/week, respectively, met the predefined criteria of ≥90% reduction in free TNF-α at the biophase. TNF-α levels in aqueous humour were anticipated to be the most sensitive to detect possible formulation issues. Formulation emptying 10, 4 or 8 weeks for adalimumab, golimumab and infliximab, respectively, before next administration triggered TNF-α reaching pathological levels at week 24 post-dose. Conclusions: This work underscores the potential of new approach methodologies in the preclinical drug development of sustained-release formulations for intravitreal administration in ocular inflammatory disorders with less animal testing and without compromising the accuracy of model-informed predictions for human translation.